Madrigal Pharmaceuticals

Yahoo Finance • 3 days ago

Viking Therapeutics, Genfit, Sagimet jump as Novo to buy Akero

Viking Therapeutics (NASDAQ:VKTX [https://seekingalpha.com/symbol/VKTX]) and other biotechs advancing drugs for a liver disease called metabolic dysfunction-associated steatohepatitis (MASH) gained on Thursday as the MASH space witnessed t... Full story

Yahoo Finance • 5 days ago

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today an... Full story

Yahoo Finance • 12 days ago

Stocks of possible M&A targets have been crushing the market. Goldman says these 6 are the most likely to get bought.

Mergers and acquisitions activity has surged in 2025, with a 29% increase in deal value. Goldman Sachs predicts another 15% rise in M&A deals in 2026, boosting candidate valuations. It flagged a list of firms it sees as M&A targets. Here a... Full story

Yahoo Finance • 16 days ago

Analysts See 11% Upside For JHML

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied... Full story

Yahoo Finance • last month

Novo Nordisk Eyes New Arena Amid Weight-Loss Market Pressure

Novo Nordisk stock remains under pressure this year. But the company is now launching Wegovy in MASH treatment. Can it make a comeback? Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Piper Sandler initiates Inventiva stock with Overweight rating on MASH potential

Investing.com - Piper Sandler initiated coverage on Inventiva SA (NASDAQ:IVA), currently valued at $730 million, with an Overweight rating and a $26.00 price target on Wednesday. The stock has shown impressive momentum, gaining over 88% in... Full story

Yahoo Finance • 2 months ago

Do You Believe in the Upside Potential of Madrigal Pharmaceuticals (MDGL)?

Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. Global markets saw an incredible but volatile second quarter, shift... Full story

Yahoo Finance • 2 months ago

Madrigal Pharmaceuticals stock neutral at Cantor as IP expert weighs in on dosing patent

Investing.com - Cantor Fitzgerald maintained its Neutral rating on Madrigal Pharmaceuticals (NASDAQ:MDGL), which has seen its stock surge over 63% in the past year and is currently trading near its 52-week high of $414.50, after hosting an... Full story

Yahoo Finance • 2 months ago

Madrigal gets EU nod for its MASH treatment

[Human Internal Digestive Organ Liver Anatomy] magicmine/iStock via Getty Images Madrigal Pharmaceuticals (NASDAQ:MDGL [https://seekingalpha.com/symbol/MDGL]) has received conditional marketing approval from the European Commission for Re... Full story

Yahoo Finance • 2 months ago

Madrigal Pharmaceuticals stock rises as EU approves MASH treatment

Investing.com - Madrigal Pharmaceuticals (NASDAQ:MDGL) stock gained Wednesday after the European Commission approved its MASH treatment REZDIFFRA, making it the first approved medication for this liver condition in the European Union. The... Full story

Yahoo Finance • 2 months ago

Madrigal's MASH treatment Rezdiffra receives EU approval

CONSHOHOCKEN, Pa. - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) announced Tuesday that the European Commission has granted conditional marketing authorization for Rezdiffra (resmetirom) to treat adults with noncirrhotic metabolic dysfunct... Full story

Yahoo Finance • 2 months ago

Madrigal Receives European Commission Approval for Rezdiffra™ (resmetirom) for the Treatment of MASH with Moderate to Advanced Liver Fibrosis

Rezdiffra is the first and only medication approved for people living with MASH in the European Union Conditional marketing authorization is based on positive results from the pivotal Phase 3 MAESTRO-NASH trial demonstrating Rezdiffra redu... Full story

Yahoo Finance • 2 months ago

Madrigal Pharmaceuticals' general counsel sells $479,626 in stock

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) General Counsel Kelley Shannon T. sold a total of 1,324 shares of common stock on August 18, 2025, generating approximately $479,626. The transaction comes as the stock trades near its 52-week hig... Full story

Yahoo Finance • 2 months ago

Novo Nordisk Rallied On Wegovy's Newest Approval. But This Rival Rallied More.

Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Madrigal Pharmaceuticals stock reaches all-time high at 378.0 USD

Madrigal Pharmaceuticals (NASDAQ:MDGL) Inc. ($8.38B market cap) has achieved a significant milestone as its stock reached an all-time high of 378.0 USD. This marks a notable achievement for the company, reflecting a robust performance with... Full story

Yahoo Finance • 2 months ago

Stocks Mixed Before Trump-Zelenskiy Meeting and Retailer Earnings

The S&P 500 Index ($SPX) (SPY) today is down by -0.03%, the Dow Jones Industrials Index ($DOWI) (DIA) is up by +0.03%, and the Nasdaq 100 Index ($IUXX) (QQQ) is down by -0.09%.  September E-mini S&P futures (ESU25) are down -0.04%, and Sep... Full story

Yahoo Finance • 2 months ago

Madrigal Pharmaceuticals stock maintains Buy rating at Goldman Sachs amid Wegovy approval

Investing.com - Goldman Sachs has reiterated its Buy rating and $567.00 price target on Madrigal Pharmaceuticals (NASDAQ:MDGL), which is currently trading near its 52-week high of $377.46 and has delivered a 47% return over the past year,... Full story

Yahoo Finance • 2 months ago

Novo Nordisk Pops On A New Wegovy Approval, Dragging Hard On Madrigal Pharma

Novo Nordisk stock jumped Monday after the FDA approved the company's obesity drug, Wegovy, as a treatment for MASH. Continue Reading View Comments... Full story

Yahoo Finance • 2 months ago

Madrigal stock falls after Novo Nordisk’s Wegovy wins FDA approval for MASH

Investing.com -- Madrigal Pharmaceuticals (NASDAQ:MDGL) stock declined 4% in pre-market trading Monday after the FDA approved Novo Nordisk’s (NYSE:NVO) Wegovy for treating adults with noncirrhotic metabolic dysfunction-associated steatohep... Full story

Yahoo Finance • 2 months ago

Novo Nordisk's Wegovy Snags Conditional FDA Nod For Fatty Liver Disease

On Saturday, the U.S. Food and Drug Administration (FDA) approved an additional indication for Novo Nordisk A/S’ (NYSE:NVO) Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for noncirrhotic metabolic dysfunct... Full story